company background image
REPL logo

Replimune Group NasdaqGS:REPL Stock Report

Last Price

US$8.37

Market Cap

US$581.0m

7D

5.9%

1Y

-64.9%

Updated

14 Jun, 2024

Data

Company Financials +

Replimune Group, Inc.

NasdaqGS:REPL Stock Report

Market Cap: US$581.0m

REPL Stock Overview

A clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer.

REPL fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Replimune Group, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Replimune Group
Historical stock prices
Current Share PriceUS$8.37
52 Week HighUS$24.33
52 Week LowUS$4.92
Beta1.16
1 Month Change22.83%
3 Month Change-1.93%
1 Year Change-64.93%
3 Year Change-76.37%
5 Year Change-38.04%
Change since IPO-44.82%

Recent News & Updates

Recent updates

Replimune: Continuing To Justify The Bear Thesis (For Now)

May 22

Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

Feb 06
Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

Replimune: The Fall Is Justified, As Virus Therapy Fails Again In Cancer

Jan 23

Calculating The Intrinsic Value Of Replimune Group, Inc. (NASDAQ:REPL)

Dec 25
Calculating The Intrinsic Value Of Replimune Group, Inc. (NASDAQ:REPL)

Is Replimune Group (NASDAQ:REPL) A Risky Investment?

Jul 13
Is Replimune Group (NASDAQ:REPL) A Risky Investment?

Is Replimune Group (NASDAQ:REPL) Using Debt In A Risky Way?

Apr 05
Is Replimune Group (NASDAQ:REPL) Using Debt In A Risky Way?

A Look At The Fair Value Of Replimune Group, Inc. (NASDAQ:REPL)

Jan 06
A Look At The Fair Value Of Replimune Group, Inc. (NASDAQ:REPL)

Replimune secures $200M term loan

Oct 07

Replimune: Recent Developments Strengthen Bull Thesis

Aug 12

Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

Aug 06
Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

Replimune Group GAAP EPS of -$0.78 misses by $0.15

Aug 04

Replimune Group, Inc. (NASDAQ:REPL) Shares Could Be 23% Below Their Intrinsic Value Estimate

Jun 24
Replimune Group, Inc. (NASDAQ:REPL) Shares Could Be 23% Below Their Intrinsic Value Estimate

We're Not Very Worried About Replimune Group's (NASDAQ:REPL) Cash Burn Rate

Apr 04
We're Not Very Worried About Replimune Group's (NASDAQ:REPL) Cash Burn Rate

Companies Like Replimune Group (NASDAQ:REPL) Are In A Position To Invest In Growth

Dec 16
Companies Like Replimune Group (NASDAQ:REPL) Are In A Position To Invest In Growth

Replimune: In The 'Buy Zone' Again

Oct 01

Estimating The Fair Value Of Replimune Group, Inc. (NASDAQ:REPL)

Sep 02
Estimating The Fair Value Of Replimune Group, Inc. (NASDAQ:REPL)

Replimune Group (NASDAQ:REPL) Is In A Strong Position To Grow Its Business

May 24
Replimune Group (NASDAQ:REPL) Is In A Strong Position To Grow Its Business

Replimune: Oncolytic Immunotherapy Pioneer Gaining Momentum In The Clinic

Apr 30

We're Interested To See How Replimune Group (NASDAQ:REPL) Uses Its Cash Hoard To Grow

Feb 08
We're Interested To See How Replimune Group (NASDAQ:REPL) Uses Its Cash Hoard To Grow

Replimune Group EPS misses by $0.03

Feb 04

Dosing underway in Replimune's early-stage cancer study with gene therapy

Jan 05

Replimune: Interesting Developer Of Oncolytic Immunotherapies

Dec 06

Replimune Group EPS misses by $0.02

Nov 05

Shareholder Returns

REPLUS BiotechsUS Market
7D5.9%0.02%1.2%
1Y-64.9%6.7%20.6%

Return vs Industry: REPL underperformed the US Biotechs industry which returned 7.4% over the past year.

Return vs Market: REPL underperformed the US Market which returned 20.5% over the past year.

Price Volatility

Is REPL's price volatile compared to industry and market?
REPL volatility
REPL Average Weekly Movement13.1%
Biotechs Industry Average Movement10.4%
Market Average Movement5.8%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.9%

Stable Share Price: REPL's share price has been volatile over the past 3 months.

Volatility Over Time: REPL's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2015331Sush Patelwww.replimune.com

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company’s proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors.

Replimune Group, Inc. Fundamentals Summary

How do Replimune Group's earnings and revenue compare to its market cap?
REPL fundamental statistics
Market capUS$580.99m
Earnings (TTM)-US$215.79m
Revenue (TTM)n/a

0.0x

P/S Ratio

-2.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
REPL income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$215.79m
Earnings-US$215.79m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-3.51
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio12.0%

How did REPL perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.